FARN:LON
Faron Pharmaceuticals Oy
36,60 GBX
arrow_upward
+0,27%(+0,100) 1K
12-okt, 16:30:00 (GMT+1) · GBX
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoFARN tikeri uchun statistika yaratilmoqda...
Ochish
35,06 GBX
Yuqori
38,00 GBX
Past
35,00 GBX
Bozor kapitali
74,16 mln
Oʻrtacha hajm
42,63 ming
Hajmi
7,06 ming
52 haftalik eng yuqori
193,58 GBX
52 haftalik eng past
34,00 GBX
Aksiya boʻyicha daromad
-0,10 GBX
Muomaladagi aksiyalar
31,03 mln
Xodimlar soni
36
Ochish
35,06 GBX
Yuqori
38,00 GBX
Past
35,00 GBX
Bozor kapitali
74,16 mln
Oʻrtacha hajm
42,63 ming
Hajmi
7,06 ming
52 haftalik eng yuqori
193,58 GBX
52 haftalik eng past
34,00 GBX
Aksiya boʻyicha daromad
-0,10 GBX
Muomaladagi aksiyalar
31,03 mln
Xodimlar soni
36
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
New York Post
·
1 soat oldin
NYSE's opening bell honors Italian Americans who beat stereotypes to reach pinnacle of finance
Simply Wall Street
·
36 daqiqa oldin
What Does Microsoft (MSFT) Gain From Its New Maia 300 AI Chip?
Yahoo
·
57 daqiqa oldin
Nasdaq ends lower as oil prices surge ahead of earnings, economic data
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy haqida